Mouse models of frontotemporal dementia

Annals of Neurology

Volumn 72, Issue 6, 2012, Pages 837-849

  Roberson, Erik D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHARGED MULTIVESICULAR PROTEIN 2B; PROGRANULIN; PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENE MUTATION; LOSS OF FUNCTION MUTATION; MOLECULAR GENETICS; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PYRAMIDAL NERVE CELL;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FRONTOTEMPORAL DEMENTIA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MOLECULAR BIOLOGY; PROTEINS; RNA-BINDING PROTEIN FUS; TAU PROTEINS;

EID: 84872000265     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23722     Document Type: Article

References (133)

1. Ratnavalli E, Brayne C, Dawson K, Hodges JR,. The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615-1621. (Pubitemid 34602891)
2. Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 2005; 65: 719-725. (Pubitemid 41285851)
3. Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562. (Pubitemid 35477048)
4. Strand AD, Aragaki AK, Baquet ZC, et al. Conservation of regional gene expression in mouse and human brain. PLoS Genet 2007; 3: e59.
5. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62: 42-52.
6. Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 2005; 62: 925-930. (Pubitemid 40973454)
7. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1-4.
8. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.
9. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135: 765-783.
10. Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007; 171: 227-240. (Pubitemid 47342406)
11. Ticozzi N, Leclerc AL, van Blitterswijk M, et al. Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiol Aging 2011; 32: 2096-2099.
12. Benajiba L, Le Ber I, Camuzat A, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009; 65: 470-473.
13. Gitcho MA, Bigio EH, Mishra M, et al. TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol 2009; 118: 633-645.
14. Kovacs GG, Murrell JR, Horvath S, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 2009; 24: 1843-1847.
15. Barmada SJ, Finkbeiner S,. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Rev Neurosci 2010; 21: 251-272.
16. Ou SH, Wu F, Harrich D, et al. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995; 69: 3584-3596.
17. Wu LS, Cheng WC, Hou SC, et al. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis 2010; 48: 56-62.
18. Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 2010; 285: 6826-6834.
19. Kraemer BC, Schuck T, Wheeler JM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol 2010; 119: 409-419.
20. Chiang P-M, Ling J, Jeong YH, et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A 2010; 107: 16320-16324.
21. Wu L-S, Cheng W-C, Shen C-K,. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem 2012; 287: 27335-27344.
22. Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2009; 106: 18809-18814.
23. Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2010; 107: 3858-3863.
24. Xu YF, Gendron TF, Zhang YJ, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci 2010; 30: 10851-10859.
25. Stallings NR, Puttaparthi K, Luther CM, et al. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis 2010; 40: 404-414.
26. Shan X, Chiang PM, Price DL, Wong PC,. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 2010; 107: 16325-16330.
27. Tsuchiya K, Ikeda K, Mimura M, et al. Constant involvement of the Betz cells and pyramidal tract in amyotrophic lateral sclerosis with dementia: a clinicopathological study of eight autopsy cases. Acta Neuropathol 2002; 104: 249-259. (Pubitemid 36075385)
28. Seeley WW, Carlin DA, Allman JM, et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol 2006; 60: 660-667. (Pubitemid 46048483)
29. Tsai K-J, Yang C-H, Fang Y-H, et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med 2010; 207: 1661-1673.
30. Igaz LM, Kwong LK, Lee EB, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 2011; 121: 726-738.
31. Swarup V, Phaneuf D, Bareil C, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011; 134 (pt 9): 2610-2626.
32. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006; 15: 2988-3001. (Pubitemid 44530703)
33. Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol 2011; 68: 488-497.
34. Alzheimer Disease and Frontotemporal Dementia Mutation Database. Available at: http://www.molgen.ua.ac.be/FTDMutations. Accessed March 14, 2012.
35. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-919. (Pubitemid 44285946)
36. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920-924. (Pubitemid 44285947)
37. Gijselinck I, van der Zee J, Engelborghs S, et al. Progranulin locus deletion in frontotemporal dementia. Hum Mutat 2008; 29: 53-58.
38. Mukherjee O, Wang J, Gitcho M, et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat 2008; 29: 512-521. (Pubitemid 351536990)
39. Shankaran SS, Capell A, Hruscha AT, et al. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem 2008; 283: 1744-1753.
40. Wang J, Van Damme P, Cruchaga C, et al. Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem 2010; 112: 1305-1315.
41. Kayasuga Y, Chiba S, Suzuki M, et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res 2007; 185: 110-118. (Pubitemid 47633696)
42. Yin F, Dumont M, Banerjee R, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J 2010; 24: 4639-4647.
43. Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ,. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis 2012; 45: 395-408.
44. Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 2010; 207: 117-128.
45. Ahmed Z, Sheng H, Xu YF, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 2010; 177: 311-324.
46. Kao AW, Eisenhut RJ, Martens LH, et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci U S A 2011; 108: 4441-4446.
47. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011; 332: 478-484.
48. Petkau TL, Neal SJ, Orban PC, et al. Progranulin expression in the developing and adult murine brain. J Comp Neurol 2010; 518: 3931-3947.
49. Smith KR, Damiano J, Franceschetti S, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 2012; 90: 1102-1107.
50. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36: 377-381. (Pubitemid 38437260)
51. Kovach MJ, Waggoner B, Leal SM, et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001; 74: 458-475. (Pubitemid 34084655)
52. van der Zee J, Pirici D, Van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 2009; 73: 626-632.
53. Kim EJ, Park YE, Kim DS, et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol 2011; 68: 787-796.
54. Forman MS, Mackenzie IR, Cairns NJ, et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006; 65: 571-581. (Pubitemid 44288941)
55. Müller JM, Deinhardt K, Rosewell I, et al. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem Biophys Res Commun 2007; 354: 459-465. (Pubitemid 46161346)
56. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007; 72: 420-426. (Pubitemid 47570695)
57. Ju JS, Weihl CC,. Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet 2010; 19: R38-R45.
58. Custer SK, Neumann M, Lu H, et al. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19: 1741-1755.
59. Badadani M, Nalbandian A, Watts GD, et al. VCP associated inclusion body myopathy and Paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One 2010; 5: e13183.
60. Gydesen S, Brown JM, Brun A, et al. Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology 2002; 59: 1585-1594. (Pubitemid 35387067)
61. Isaacs AM, Johannsen P, Holm I, et al. Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res 2011; 8: 246-251.
62. Holm IE, Englund E, Mackenzie IR, et al. A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 2007; 66: 884-891. (Pubitemid 47530827)
63. Holm IE, Isaacs AM, Mackenzie IR,. Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol 2009; 118: 719-720.
64. Cox LE, Ferraiuolo L, Goodall EF, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One 2010; 5: e9872.
65. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005; 37: 806-808. (Pubitemid 41077105)
66. Lee JA, Beigneux A, Ahmad ST, et al. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol 2007; 17: 1561-1567. (Pubitemid 47380392)
67. Ghazi-Noori S, Froud KE, Mizielinska S, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain 2012; 135: 819-832.
68. Roberson ED,. Frontotemporal dementia. Curr Neurol Neurosci Rep 2006; 6: 481-489.
69. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256.
70. van Swieten J, Spillantini MG,. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol 2007; 17: 63-73.
71. Jeganathan S, von Bergen M, Brutlach H, et al. Global hairpin folding of tau in solution. Biochemistry 2006; 45: 2283-2293. (Pubitemid 43271328)
72. Rademakers R, Cruts M, van Broeckhoven C,. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004; 24: 277-295. (Pubitemid 39336634)
73. Goedert M, Jakes R,. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005; 1739: 240-250. (Pubitemid 40021808)
74. Götz J, Deters N, Doldissen A, et al. A decade of tau transgenic animal models and beyond. Brain Pathol 2007; 17: 91-103.
75. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005; 25: 5446-5454. (Pubitemid 40770926)
76. Spires TL, Orne JD, SantaCruz K, et al. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006; 168: 1598-1607.
77. de Calignon A, Fox LM, Pitstick R, et al. Caspase activation precedes and leads to tangles. Nature 2010; 464: 1201-1204.
78. Mocanu MM, Nissen A, Eckermann K, et al. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy. J Neurosci 2008; 28: 737-748. (Pubitemid 351159036)
79. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-351. (Pubitemid 46161268)
80. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476-481. (Pubitemid 40994688)
81. Sydow A, Van der Jeugd A, Zheng F, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 2011; 31: 2511-2525.
82. Hoover BR, Reed MN, Su J, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010; 68: 1067-1081.
83. Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012; 73: 1216-1227.
84. Frost B, Jacks RL, Diamond MI,. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12845-12852.
85. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913.
86. de Calignon A, Polydoro M, Suárez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-697.
87. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.
88. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005; 102: 6990-6995. (Pubitemid 40675429)
89. Le Corre S, Klafki HW, Plesnila N, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 2006; 103: 9673-9678. (Pubitemid 43955883)
90. Brunden KR, Zhang B, Carroll J, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010; 30: 13861-13866.
91. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM,. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-9129. (Pubitemid 47312068)
92. Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011; 286: 34457-34467.
93. Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011; 6: e26860.
94. O'Leary JC III, Li Q, Marinec P, et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010; 5: 45.
95. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268.
96. Hodges J,. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 2012; 135: 652-655.
97. Lu H, Zou Q, Gu H, et al. Rat brains also have a default mode network. Proc Natl Acad Sci U S A 2012; 109: 3979-3984.
98. Rakic P,. Evolution of the neocortex: a perspective from developmental biology. Nat Rev Neurosci 2009; 10: 724-735.
99. Boccardi M, Sabattoli F, Laakso MP, et al. Frontotemporal dementia as a neural system disease. Neurobiol Aging 2005; 26: 37-44. (Pubitemid 39600589)
100. Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008; 65: 249-255. (Pubitemid 351240789)
101. Schroeter ML, Raczka K, Neumann J, von Cramon DY,. Neural networks in frontotemporal dementia-a meta-analysis. Neurobiol Aging 2008; 29: 418-426. (Pubitemid 351215583)
102. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27: 2349-2356. (Pubitemid 46340968)
103. Taylor KS, Seminowicz DA, Davis KD,. Two systems of resting state connectivity between the insula and cingulate cortex. Hum Brain Mapp 2009; 30: 2731-2745.
104. Ibañez A, Gleichgerrcht E, Manes F,. Clinical effects of insular damage in humans. Brain Struct Funct 2010; 214: 397-410.
105. Smith KS, Tindell AJ, Aldridge JW, Berridge KC,. Ventral pallidum roles in reward and motivation. Behav Brain Res 2009; 196: 155-167.
106. LeDoux J,. The amygdala. Curr Biol 2007; 17: R868-R874.
107. Allman JM, Tetreault NA, Hakeem AY, et al. The von Economo neurons in frontoinsular and anterior cingulate cortex in great apes and humans. Brain Struct Funct 2010; 214: 495-517.
108. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
109. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134 (pt 9): 2456-2477.
110. Crawley JN,. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007; 17: 448-459. (Pubitemid 47537604)
111. Moy SS, Nadler JJ, Perez A, et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 2004; 3: 287-302. (Pubitemid 39277416)
112. Langford DJ, Crager SE, Shehzad Z, et al. Social modulation of pain as evidence for empathy in mice. Science 2006; 312: 1967-1970. (Pubitemid 43993726)
113. Jeon D, Kim S, Chetana M, et al. Observational fear learning involves affective pain system and Cav1.2 Ca2+ channels in ACC. Nat Neurosci 2010; 13: 482-488.
114. Rankin KP, Kramer JH, Mychack P, Miller BL,. Double dissociation of social functioning in frontotemporal dementia. Neurology 2003; 60: 266-271. (Pubitemid 36152020)
115. Lindzey G, Winston H, Manosevitz M,. Social dominance in inbred mouse strains. Nature 1961; 191: 474-476.
116. Rankin KP, Gorno-Tempini ML, Allison SC, et al. Structural anatomy of empathy in neurodegenerative disease. Brain 2006; 129: 2945-2956. (Pubitemid 44684515)
117. Scearce-Levie K, Roberson ED, Gerstein H, et al. Abnormal social behaviors in mice lacking Fgf17. Genes Brain Behav 2008; 7: 344-354. (Pubitemid 351490238)
118. Miller BL, Darby AL, Swartz JR, et al. Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. Dementia 1995; 6: 195-199.
119. Mendez MF, Shapira JS, Miller BL,. Stereotypical movements and frontotemporal dementia. Mov Disord 2005; 20: 742-745. (Pubitemid 41051787)
120. Greer JM, Capecchi MR,. Hoxb8 is required for normal grooming behavior in mice. Neuron 2002; 33: 23-34. (Pubitemid 34088176)
121. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007; 448: 894-900. (Pubitemid 47312780)
122. Shmelkov SV, Hormigo A, Jing D, et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 2010; 16: 598-602.
123. Josephs KA, Whitwell JL, Jack CR Jr,. Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiol Aging 2008; 29: 1859-1863.
124. Halabi C, Halabi A, Dean DL, et al. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis Assoc Disord. doi: 10.1097/WAD. 0b013e31824a7df4.
125. Werner KH, Roberts NA, Rosen HJ, et al. Emotional reactivity and emotion recognition in frontotemporal lobar degeneration. Neurology 2007; 69: 148-155. (Pubitemid 47051719)
126. Hoefer M, Allison SC, Schauer GF, et al. Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease. Brain 2008; 131: 1646-1657. (Pubitemid 351806464)
127. LeDoux J,. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003; 23: 727-738.
128. Geerts H,. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 2009; 23: 915-926.
129. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25: 402-405. (Pubitemid 32983430)
130. Ramsden M, Kotilinek L, Forster C, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005; 25: 10637-10647. (Pubitemid 41681911)
131. Götz J, Chen F, Barmettler R, Nitsch RM,. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276: 529-534. (Pubitemid 32050347)
132. Duff K, Knight H, Refolo LM, et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000; 7: 87-98. (Pubitemid 30241205)
133. Andorfer C, Kress Y, Espinoza M, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86: 582-590. (Pubitemid 36897439)